Ralliant (NYSE:RAL) Reaches New 52-Week High – Should You Buy?

Ralliant Corporation (NYSE:RAL) hit a new 52-week high during trading on Thursday . The company traded as high as $55.25 and last traded at $54.6750, with a volume of 149005 shares trading hands. The stock had previously closed at $53.83.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on RAL shares. Oppenheimer raised their price objective on shares of Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Barclays boosted their price target on Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. Weiss Ratings restated a “hold (c)” rating on shares of Ralliant in a research report on Monday, December 29th. Citigroup upgraded Ralliant from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $53.00 to $61.00 in a research report on Monday, December 8th. Finally, Royal Bank Of Canada boosted their target price on shares of Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a research note on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.00.

Ralliant Price Performance

The business has a 50-day moving average price of $50.76. The company has a quick ratio of 1.03, a current ratio of 1.49 and a debt-to-equity ratio of 0.39. The firm has a market cap of $6.06 billion and a PE ratio of 42.28.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.02. The company had revenue of $529.10 million for the quarter, compared to analyst estimates of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 23rd. Shareholders of record on Monday, December 8th were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Ralliant’s dividend payout ratio (DPR) is currently 15.75%.

Institutional Trading of Ralliant

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Ralliant by 10.7% in the third quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock valued at $637,995,000 after acquiring an additional 1,415,327 shares during the last quarter. Dodge & Cox acquired a new position in shares of Ralliant in the 2nd quarter valued at about $523,571,000. Viking Global Investors LP acquired a new position in shares of Ralliant in the 2nd quarter valued at about $257,200,000. State Street Corp acquired a new position in shares of Ralliant in the 2nd quarter valued at about $213,096,000. Finally, Flossbach Von Storch SE grew its holdings in shares of Ralliant by 1.7% during the 3rd quarter. Flossbach Von Storch SE now owns 4,152,866 shares of the company’s stock worth $181,605,000 after purchasing an additional 67,963 shares during the period.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.